ARGX vs GRFS vs NXTS Stock Comparison

Argenx Se, Grifols and Nexentis Technologies Prices as of Oct 27, 2026 Peers: Industry group
ARGX Argenx Se
$882.48 -8.0% 1M +6.3% 1Y
Market cap
$54.61B
P/E
28.8x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins
GRFS Grifols SA
$8.10 +10.2% 1M -13.6% 1Y
Market cap
$5.51B
P/E
12.1x
Revenue (TTM)
—
Div. yield
1.36%
Biotechnology Healthcare
3 wins

Head to Head

7 decided of 12

Argenx Se leads on 4 of the 12 questions below (Argenx Se 4, Grifols 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARGXGRFSNXTSLeader
Larger companyMarket capitalisation $54.61B $5.51B $473.36K ARGX
Cheaper on earningsLower P/E, profitable companies only 28.8x 12.1x 0.0x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.8x 8.6x — GRFS
Faster revenue growthRevenue growth, trailing twelve months +61.5% — — –
More profitableNet margin, trailing twelve months 32.3% — — –
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA — — 1.6x –
Higher dividend yieldTrailing dividend yield — 1.36% — –
Better 1-year returnPrice return, last 12 months +6.3% -13.6% -97.8% ARGX
Better 5-year returnAnnualised price return, 5 years +25.8%/yr -9.4%/yr -86.1%/yr ARGX
Less volatileAnnualised volatility, 1 year 36.9% 32.4% 168.9% GRFS
Higher overall scoreMean of the five percentile scores vs peers 92/100 56/100 32/100 ARGX

Percentile Scorecard

ARGXGRFSNXTS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARGXGRFSNXTS
Valuation 84 #99 of 625 99 #7 of 625 –
Growth 94 #35 of 602 – 13 #523 of 602
Profitability 98 #11 of 551 – 40 #329 of 551
Financial Health – 14 #564 of 656 43 #372 of 656
Shareholder Returns – 56 #161 of 365 –
Overall 92 56 32
  • ARGX ranked among 672 companies in Pharmaceuticals and Biotechnology
  • GRFS ranked among 672 companies in Pharmaceuticals and Biotechnology
  • NXTS ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARGXGRFSNXTSSPY
1 month -8.0%+10.2%-60.5% -0.2%
3 months +1.2%+1.2%-62.6% +3.9%
6 months +13.9%+0.4%-87.8% +8.2%
Year to date +4.9%-13.4%-95.1% +12.9%
1 year +6.3%-13.6%-97.8% +12.3%
3 years +91.9%+3.3%-99.9% +87.4%
3 years, per year +24.3%+1.1%-89.5% +23.3%
5 years +214.2%-39.0%-100.0% +67.9%
5 years, per year +25.8%-9.4%-86.1% +10.9%
10 years —-44.7%-100.0% +261.1%
10 years, per year —-5.8%-66.5% +13.7%

Risk

MeasureARGXGRFSNXTSSPY
Volatility, 1Y 36.9%32.4%168.9% 12.7%
Downside volatility, 1Y 34.6%34.1%153.3% 12.7%
Beta vs S&P 500, 1Y 0.390.952.33 1.00
Return / volatility, 1Y 0.17-0.42-0.58 0.97
Max drawdown, 5Y -38.2%-58.8%-100.0% -25.4%
From 52-week high -16.7%-16.7%-97.8% -1.2%
52-week high $1,058.90$9.72$26.04 $779.14
52-week low $663.93$7.02$0.53 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARGXGRFSNXTS
P/E now vs peer median 28.8xmedian 17.2x 12.1xmedian 17.2x 0.0xmedian 17.2x
P/S now vs peer median 9.4xmedian 9.0x 0.6xmedian 9.0x —median 9.0x
EV/EBITDA now vs peer median —median 16.3x —median 16.3x 1.5xmedian 16.3x
P/FCF now vs peer median —median 18.7x 7.8xmedian 18.7x —median 18.7x
P/B now vs peer median —median 2.2x 0.6xmedian 2.2x 0.2xmedian 2.2x
PEG now vs peer median 0.27median 0.33 —median 0.33 0.00median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARGXGRFSNXTS
Revenue $5.82B – –
Gross profit $5.24B – –
Operating income $1.74B – -$5.28M
Net income $1.88B – -$14.06M
R&D $1.80B – $532.00K
EPS (diluted) $28.43 – $-17.10
Cash & equivalents – $969.15M $7.62M
Total debt – $44.00B $3.22M
Shares (diluted) 66.03M 681.57M 816.14K
Enterprise value $54.61B $4.59B -$22.29M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARGXGRFSNXTS
P/E 28.8x 12.1x 0.0x
P/FCF – 7.8x –
P/Operating cash flow – – –
P/S 9.4x 0.6x –
P/B – 0.6x 0.2x
P/Tangible book – 1.0x -0.2x
EV/EBITDA – – 1.5x
EV/EBIT 31.4x – 1.5x
EV/Revenue 9.4x – –
EV/FCF – – –
EV/Operating cash flow – – –
PEG (3Y EPS CAGR) 0.27 – 0.00

Growth

14 metrics
MetricARGXGRFSNXTS
Revenue growth (1Y) 61.5% – –
Revenue CAGR (3Y) 80.5% – –
Gross profit growth (1Y) 62.2% – –
Gross profit CAGR (3Y) 80.0% – –
Operating income growth (1Y) 120.6% – -7.7%
Operating income CAGR (3Y) 85.1% – 3.0%
Net income growth (1Y) 22.5% – -48.2%
Net income CAGR (3Y) 115.5% – -35.8%
EPS growth (1Y) 20.9% – -567.8%
EPS CAGR (3Y) 104.8% – -45.2%
Operating cash flow growth (1Y) – – –
Operating cash flow CAGR (3Y) – – –
Free cash flow growth (1Y) – – –
Free cash flow CAGR (3Y) – – –

Profitability

14 metrics
MetricARGXGRFSNXTS
Gross margin 90.0% – –
EBITDA margin – – –
Operating margin 29.9% – –
Pretax margin 32.6% – –
Net margin 32.3% – –
FCF margin – – –
Operating cash flow margin – – –
Return on equity – – -157.0%
Return on assets – – -71.9%
Return on invested capital – – –
Return on capital employed – – -31.5%
Asset turnover – – –
Cash conversion (OCF / net income) – – –
Stock comp / revenue – – –

Financial Health

11 metrics
MetricARGXGRFSNXTS
Debt / assets – 48.9% 2.3%
Debt / equity – 1.3x 0.2x
Net debt / EBITDA – – 1.6x
Debt / FCF – – –
Liabilities / assets – 61.4% 89.8%
Equity / assets – 38.6% 10.2%
Interest coverage 10,120x – –
Current ratio – 2.5x 3.7x
Quick ratio – 0.8x 3.2x
Cash ratio – 0.4x 3.2x
Altman Z-score – – –

Shareholder Returns

7 metrics
MetricARGXGRFSNXTS
Dividend yield – 1.4% –
Net buyback yield – – –
Shareholder yield – 1.4% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARGXGRFSNXTS
Forward P/E 28.8xFY2026 8.6xFY2026 –
EPS, next fiscal year $30.63FY2026 $0.94FY2026 –
EPS growth, next FY +56.5%FY2026 +10.6%FY2026 –
EPS growth, the year after +26.9% +26.6% –
Revenue, next fiscal year $6.08BFY2026 $8.88BFY2026 –
Revenue growth, next FY +43.1%FY2026 +0.0%FY2026 –
Revenue growth, the year after +22.9% +10.3% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARGXGRFSNXTS
Held by institutions 46.1% 21.0% –
Institutions holding 504 166 –
Change in shares held, QoQ -2.0% -0.5% –
Institutions buying 264 73 –
Institutions selling 160 65 –
Buyers to sellers 1.65 1.12 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARGXGRFSNXTS
ARGX 1.00 0.15 0.12
GRFS 0.15 1.00 0.04
NXTS 0.12 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ARGX, GRFS and NXTS?

Argenx Se (ARGX) is the largest by market capitalisation: Argenx Se (ARGX) $54.61B, Grifols (GRFS) $5.51B, Nexentis Technologies (NXTS) $473.36K.

Which stock is cheaper, ARGX, GRFS and NXTS?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Argenx Se (ARGX) 28.8x, Grifols (GRFS) 12.1x, Nexentis Technologies (NXTS) 0.0x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Argenx Se (ARGX) 28.8x, Grifols (GRFS) 8.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which stock has performed better?

Over the past year Argenx Se (ARGX) returned the most: Argenx Se (ARGX) +6.3%, Grifols (GRFS) -13.6%, Nexentis Technologies (NXTS) -97.8%. Over five years, Argenx Se (ARGX) compounded fastest (Argenx Se (ARGX) +25.8%/yr, Grifols (GRFS) -9.4%/yr, Nexentis Technologies (NXTS) -86.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Grifols (GRFS) 1.36%. Argenx Se (ARGX) and Nexentis Technologies (NXTS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Grifols (GRFS) has been the steadiest (Argenx Se (ARGX) 36.9%, Grifols (GRFS) 32.4%, Nexentis Technologies (NXTS) 168.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ARGX, GRFS and NXTS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.